Dronabinol
- Generic Name
- Dronabinol
- Brand Names
- Marinol, Sativex, Syndros
- Drug Type
- Small Molecule
- Chemical Formula
- C21H30O2
- CAS Number
- 1972-08-3
- Unique Ingredient Identifier
- 7J8897W37S
- Background
Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effects of smoking cannabis such as increased ...
- Indication
Dronabinol is indicated for the treatment of anorexia associated with weight loss in patients with AIDS, and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.
- Associated Conditions
- Anorexia, Chemotherapy-Induced Nausea and Vomiting
- Associated Therapies
- -
Palonosetron and Dexamethasone With or Without Dronabinol in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy For Cancer
- First Posted Date
- 2007-11-04
- Last Posted Date
- 2020-10-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 62
- Registration Number
- NCT00553059
- Locations
- 🇺🇸
University of Texas M.D. Anderson, Houston, Texas, United States
🇺🇸CCOP - Greenville, Greenville, South Carolina, United States
🇺🇸Cancer Research for the Ozarks, Springfield, Missouri, United States
Ph1 Marinol Interaction Study - Part 2 - 1
- First Posted Date
- 2007-06-22
- Last Posted Date
- 2017-01-12
- Lead Sponsor
- National Institute on Drug Abuse (NIDA)
- Target Recruit Count
- 12
- Registration Number
- NCT00490269
- Locations
- 🇺🇸
Uniformed Services University of Health Science, Bethesda, Maryland, United States
Effectiveness Study of Dronabinol and BRENDA for the Treatment of Cannabis Withdrawal
- Conditions
- Interventions
- First Posted Date
- 2007-05-31
- Last Posted Date
- 2019-07-29
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 61
- Registration Number
- NCT00480441
- Locations
- 🇺🇸
Treatment Research Center at the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Ph1 Marinol Interaction Study - Part 1 - 1
- Conditions
- First Posted Date
- 2007-02-21
- Last Posted Date
- 2017-01-16
- Lead Sponsor
- National Institute on Drug Abuse (NIDA)
- Target Recruit Count
- 6
- Registration Number
- NCT00438139
- Locations
- 🇺🇸
Uniformed Services University of Health Science, Bethesda, Maryland, United States
Efficacy of Dronabinol for the Treatment of Cervical Dystonia
- Conditions
- First Posted Date
- 2007-01-05
- Last Posted Date
- 2008-09-09
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 38
- Registration Number
- NCT00418925
- Locations
- 🇨🇦
Toronto Western Hospital, Toronto, Ontario, Canada
Sativex Versus Placebo When Added to Existing Treatment for Central Neuropathic Pain in MS
- First Posted Date
- 2006-10-23
- Last Posted Date
- 2013-06-24
- Lead Sponsor
- GW Pharmaceuticals Ltd
- Target Recruit Count
- 339
- Registration Number
- NCT00391079
- Locations
- 🇨🇦
Dalhousie MS Research Clinic, Halifax, Nova Scotia, Canada
🇨🇦MS Clinic, UBC Purdy Pavilion, Vancouver, British Columbia, Canada
🇨🇦London Health Sciences Centre / University Hospital, London, Ontario, Canada
Effect of Delta-9-Tetrahydrocannabinol on the Prevention of Chronic Pain in Patients With Acute CRPS (ETIC-Study)
- Conditions
- First Posted Date
- 2006-09-18
- Last Posted Date
- 2008-06-30
- Lead Sponsor
- Ludwig-Maximilians - University of Munich
- Target Recruit Count
- 100
- Registration Number
- NCT00377468
- Locations
- 🇩🇪
Department of Anesthesiology, Interdisciplinary Pain Clinic Grosshadern, Universitiy of Munich, Munich, Germany
Effect of Lofexidine and Oral THC on Marijuana Withdrawal and Relapse
- Conditions
- Interventions
- First Posted Date
- 2006-09-08
- Last Posted Date
- 2013-02-05
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 8
- Registration Number
- NCT00373503
- Locations
- 🇺🇸
New York State Psychiatric Institute, New York, New York, United States
A Pilot Study of Dronabinol for Adult Patients With Primary Gliomas
- First Posted Date
- 2006-04-17
- Last Posted Date
- 2014-07-16
- Lead Sponsor
- Duke University
- Target Recruit Count
- 33
- Registration Number
- NCT00314808
- Locations
- 🇺🇸
Preston Robert Tisch Brain Tumor Center at Duke University Medical Center, Durham, North Carolina, United States
Dronabinol Treatment for Marijuana Addiction
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2019-04-24
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 156
- Registration Number
- NCT00217971
- Locations
- 🇺🇸
Research Foundation for Mental Hygiene, Inc., New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.